Journal of Medicines Development Sciences

Editor-in-ChiefBoeynaems, Jean-Marie

ISSN: 2382-6371 (Online)

ISSN: 2382-6363 (Print)

Journal Abbreviation: J Med Dev Sci

Article Processing Charges (APC): Click here for more details

Publishing Model: Open Access

Journal no: 1P

About the Journal

The Journal of Medicines Development Sciences focuses on the discovery and development of new medicinal products. The journal publishes original research articles on medicinal chemistry, experimental pharmacology including pharmacokinetics, preclinical safety, clinical pharmacology, pharmacogenomics, clinical research, pharmacoepidemiology and pharmacoeconomics. The journal also publishes brief reports on new research findings and review articles. Articles encouraging taking the therapy from bench to bedside and creating a broad readership of young researchers, clinicians and scientists are welcome.

Recently Published Articles

Review Article

Akiko Kishi, Ichiro Uchida, Daisuke Koide, Kyoko Imamura
1 Views, 2 PDF Downloads

Development of new medicines has become increasingly difficult with less possibility of success in seeds-finding and ever rising operational costs. Failure to comply with ethical standards for human research protection also erodes social trust in clinical development. In order to develop competence of professionals in medicines development such as clinical investigators and drug development scientists, a variety of educational courses and training programs have been developed and executed worldwide. As Japan is no exception and shares the same concerns, significant governmental and non-governmental efforts have been made to invest in the development of academic educational courses and adherence to international standards. This article introduces examples of the adoption of technologies to realize a user-friendly and sustainable learning management as well as an adaptation of syllabuses and core curricula to meet international standards in the era of global medicines development.

PDF

Conference Highlights

Dipak Kalra, Mats Sundgren, Brecht Claerhout, Pierre Meulien, Bart Vannieuwenhuyse, Peter Singleton, Terje Peetso, Veli Stroetmann, Petra Wilson, Mary Baker, Pascal Coorevits, John O’Brien, Georges De Moor
1 Views, 17 PDF Downloads

The European Institute for Innovation through Health Data (i~HD) has been formed as one of the sustainable entities arising from the Electronic Health Records for Clinical Research (EHR4CR) and SemanticHealthNet projects, in collaboration with other European Commission projects and initiatives. The vision of i~HD is to become the European organisation of reference for guiding and catalysing the best, most efficient and trustworthy uses of health data and interoperability, for optimizing health and knowledge discovery.

i~HD has been established in recognition that there is a need to tackle areas of challenge in the successful scaling up of innovations that rely on high-quality and interoperable health data, to sustain and propagate the results of eHealth research, and to address current-day obstacles to using health data. i~HD was launched at an inaugural conference in Paris, in March 2016. This was attended by over 200 European clinicians, healthcare providers and researchers, representatives of the pharma industry, patient associations, health professional associations, the health ICT industry and standards bodies. The event showcased issues and approaches, that are presented in this paper to highlight the activities that i~HD intends to pursue as enablers of the better uses of health data, for care and research.

PDF

Review Article

Anita Aperia, Jorgen Dirach, Mike Hardman, Christa Janko, Jeff Kipling, Rosan Kreeftmeijer-Vegter, Rebecca Ludwig, Lena Scott, Armel Stockis
9 Views, 4 PDF Downloads

“No research without trained researchers” has become the mantra of the EU-funded Innovative Medicines Initiative (IMI) education and training projects. However, it is often hard to determine the type of training required at different stages of a scientist’s career. The situation is further complicated by the constantly changing environment, e.g. the growth of disruptive technologies, societal expectations of biomedical sciences, the greater need for multi-disciplinary collaborations, and conservative or changing regulatory requirements. This article summarises the experience from a series of five EMTRAIN Public Private Partnership PhD workshops that included both scientific and transferrable skill training. This is followed by an example of a recently developed training programme, including a competency profile, for translational research and medicines development; the C-COMEND teaching programme. The emphasis is on competencies as a new currency for continuing professional development. Finally, this paper describes what we consider to be the next steps required by the scientific community to address solutions to the current training challenges so that society can benefit from the innovations that only science can provide.

PDF

Original Research Article

Ana Paula Ruenis, João Massud Filho
64 Views, 59 PDF Downloads
Brazil is one of the world´s largest economies and pharmaceutical markets, having the Brazilian government as an important purchaser. There are strong local companies that have grown sustainably after the introduction of generics and are investing in both incremental and radical innovation. However, research and development (R&D) expenditures are still modest; this could be explained by a combination of economic and political uncertainty in the past few years and a bureaucratic, complex regulatory framework. New regulations, efforts to reduce ethical and regulatory review timelines, and a Senate bill aimed to accomplish that goal should constitute the definitive regulatory landmark for boosting clinical research. In addition to government investments they have given a breath of relief in the market, as Brazil is trying to, once again, gain momentum as a “must-go” country for clinical development. Non-profit associations such as the Brazilian Society of Pharmaceutical Medicine (Sociedade Brasileira de Medicina Farmacêutica-SBMF), the Brazilian Association of CROs (Associação Brasileira de Organizações Representativas de Pesquisa Clínica-ABRACRO), the Brazilian Clinical Research Alliance (Aliança Pesquisa Clínica Brasil), amongst others, helped to give the impulse to trigger such changes. It is time to invest heavily in developing educational programs to address the growing need for clinical development scientists and physicians.
PDF

Original Research Article

Victoria Elegant
75 Views, 147 PDF Downloads

The Asia Pacific region is an extremely diverse region, characterized by heterogeneity from a number of aspects, including culture, religion, economics, landscapes, and languages. This also applies to the standard of medical care and the regulatory requirements for approval of drugs in the region. Developed economies such as Japan and Australia have requirements which are not dissimilar to those of the EU and USA, but still have their own unique requirements. The developing economies all have their own requirements. In the ASEAN region there is harmonization of the dossier format, but each country still has local requirements. The region has seen significant growth in clinical trial activity, both to satisfy local registration and safety requirements and to help accelerate global trial patient recruitment. There is a clear need for training in all aspects of medical, regulatory, clinical and safety aspects of medicines development, which is being addressed through several organizations and at different locations in the region.

PDF

Original Research Article

Elyse I. Summers
54 Views, 64 PDF Downloads
This year marks the 15th anniversary of the founding of the Association for the Accreditation of Human Research Protection Programs (AAHRPP), an organization that has been instrumental in strengthening protections for research participants. AAHRPP was established by seven Founding Members in response to a series of high-profile incidents that shook the foundation of the U.S. research enterprise. The Founding Members viewed voluntary accreditation as one way to strengthen research protections and restore and preserve public trust. Today, AAHRPP accreditation is widely regarded as the gold standard for research protections. To attain accreditation, organizations must demonstrate that they adhere to rigorous standards covering three domains: The Organization, The Institutional Review Board or Ethics Committee, and Researcher and Research Staff. The emphasis is on system-wide policies and procedures that strengthen an organization’s commitment to participants and help ensure a more consistent, more effective approach to protecting them. Because AARHPP accreditation is considered an objective indicator of quality, the benefits to accredited organizations can be considerable. Their accreditation status sends a signal — to potential research partners, to sponsors and other funders, and to research participants — that the organization has the systems in place to conduct research in a scientifically and ethically sound manner.
PDF

Review Article

Dorothée Cammarata, Abduelhakem Ben Addi, Eva D’Amico, Bernard Robaye
73 Views, 59 PDF Downloads
Numerous studies have demonstrated the role of uridine diphosphate (UDP) and its P2Y6 receptor in the inflammatory reaction and innate immunity. However, the importance of the P2Y6 receptor in the adaptive immune response remains unclear. In this study, we demonstrate that the P2Y6 receptor is functionally expressed in murine bone marrow dendritic cells (BMDC). UDP induced a Ca2+ transient in these cells that was decreased in P2Y6-deficient mice. UDP also increased the endocytosis of fluorescein isothiocyanate-dextran (FITC-dextran) and amplified the secretion of interleukin 12-p70 (IL-12p70) induced by CpG; these responses were abolished in P2Y6-deficient mice. In vivo experiments showed that the serum level of specific IgG2c after immunisation with ovalbumin was decreased in P2Y6-deficient mice, while the level of specific IgG1 was unchanged. These data suggest that the P2Y6-mediated effects of UDP on myeloid dendritic cells play a role in the in vivo Th1 skewing of the immune response.
PDF

Review Article

Franck Atienzar, Annie Delaunois, Frédéric Brouta, Miranda Cornet, Renaud Fleurance, Helga Gerets, Stéphanie Glineur, Catrin Hasselgren, Andrea Kiessling, Andre Nogueira da Costa, Marie-Luce Rosseels, Karen Tilmant, Jean-Pierre Valentin
276 Views, 164 PDF Downloads
Understanding and reducing attrition rate remains a key challenge in drug development. Preclinical and clinical safety issues still represent about 40% of drug discontinuation, of which cardiac and liver toxicities are the leading reasons. Reducing attrition rate can be achieved by various means, starting with a comprehensive evaluation of the potential safety issues associated to the primary target followed by an evaluation of undesirable secondary targets. To address these risks, a risk mitigation plan should be built at very early development stages, using a panel of in silico, in vitro, and in vivo models. While most pharmaceutical companies have developed robust safety strategies to de-risk genotoxicity and cardiotoxicity issues, partly driven by regulatory requirements; safety issues affecting other organs or systems, such as the central nervous system, liver, kidney, or gastro-intestinal system are less commonly addressed during early drug development. This paper proposes some de-risking strategies that can be applied to these target organ systems, including the use of novel biomarkers that can be easily integrated in both preclinical and clinical studies. Experiments to understand the mechanisms’ underlying toxicity are also important. Two examples are provided to demonstrate how such mechanistic studies can impact drug development. Novel trends in investigative safety are reviewed, such as computational modeling, mitochondrial toxicity assessment, and imaging technologies. Ultimately, understanding the predictive value of non-clinical safety testing and its translatability to humans will enable to optimize assays in order to address the key objectives of the drug discovery process, i.e., hazard identification, risk assessment, and mitigation.
PDF

Editorial

Jean-Marie Boeynaems
58 Views, 24 PDF Downloads
Welcome to the 3rd issue of the Journal of Medicines Development Sciences. Like previous issues it contains articles covering the entire process of drug development from target identification to drug registration.
PDF

Review Article

Bernd Rosenkranz, Michael Reid, Elizabeth Allen
47 Views, 38 PDF Downloads
Africa is one of the world’s fastest-growing economic regions, with a rise in its pharmaceutical industry value from $4.7 billion in 2003 to $20.8 billion in 2013. Multinational pharmaceutical companies are becoming more active in drug production and clinical trials across Africa, and there is an increase in the number of local companies engaged in medicines development and marketing. Such expansion of the local pharmaceutical industry requires trained pharmaceutical specialists to support it. The current situation and future requirements for local medicines development, regulation, education and training needs are discussed.
PDF
Read more

Indexing and Archiving

Journal of Medicines Development Sciences (JMDS) aims to be indexed by world-recognized databases, for example, PubMed, Scopus and Science Citation Index (SCI). SOM has been indexed and archived by several databases:

Editorial Board

Editor-in-Chief

Jean Marie BoeynaemsUniversité Libre de BruxellesBelgium

Associate Editors

Kazuhide InoueKyushu UniversityJapan
Sandor Kerpel-FroniusSemmelweis UniversityHungary
Bernd RosenkranzStellenbosch UniversitySouth Africa
Jean-Pierre ValentinUCB PharmaBelgium

Editorial Board Members

Abdelilah AboussekhraKing Faisal Hospital & Research CentreSaudi Arabia
Ronald BarbarasCerenis TherapeuticsFrance
Dominique DuboisPatient Value Solutions (PVS) ConsultancyBelgium
Vincent DupriezPerkin-Elmer Life SciencesBelgium
Alison GartlandUniversity of SheffieldUnited Kingdom
Michel GillardUCB PharmaBelgium
Schuichi KoizumiUniversity of YamanashiJapan
Eduardo LazarowskiUniversity of North CarolinaUnited States
Jesus PintorComplutense University of MadridSpain
Sam SalekInstitute for Medicines DevelopmentUnited Kingdom
Eckart SchwarzGSKUnited States
Honorio SilvaACRESUnited States
David VermijlenUniversité Libre de BruxellesBelgium

Focus and Scope

The Journal of Medicines Development Sciences focuses on the discovery and development of new medicinal products. The journal publishes original research articles on medicinal chemistry, experimental pharmacology including pharmacokinetics, preclinical safety, clinical pharmacology, pharmacogenomics, clinical research, pharmacoepidemiology and pharmacoeconomics. The journal also publishes brief reports on new research findings and review articles. Articles encouraging taking the therapy from bench to bedside and creating a broad readership of young researchers, clinicians and scientists are welcome.

For Authors

  • A manuscript would not be accepted if it has been published or is currently under consideration for publication in any other journals. The author will need to notify the editorial team if the data in their submission has been presented in conferences.

  • Authorship should be limited to people who have contributed substantially to the work. Authors must indicate their specific contributions to the published work. This information should be listed in the manuscript under the section ‘Author Contribution’. Examples of contributions include: designed research, performed research, contributed new reagents or analytic tools, analyzed data, wrote the paper.

    For more information on submission’s format, please refer to the ‘Author Guidelines’ link accessible from the ‘About’ button at the top row of this page.

    The corresponding author should be clearly indicated for all manuscripts submitted. A maximum of two corresponding authors are allowed for the responsibilities associated. The corresponding author(s) is responsible for:

    • Obtaining permission from all the authors mentioned in the manuscript
    • Ensuring adherence to all editorial and submission policies and for any communications and actions that may be necessary after publication
    • Including written permission from the authors of the work concerned for any mention of any unpublished material included in the manuscript, e.g. data from manuscripts-in-press, personal communication, or work in preparation.
  • The author has to provide the authorization of no conflict with any financial body or funding agency that might influence the results or interpretation of their manuscript. All authors, members, reviewers and editors must disclose any association that poses a conflict of interest in connection with the manuscript. The corresponding author will be asked to sign a form behalf of all of the authors regarding potential conflicts of interest at the time of acceptance.

  • The editorial team does not approve of any plagiarism attempts. iThenticate will be utilized at the editor’s discretion to verify the originality of submitted manuscripts. If plagiarism is detected during the review process the manuscript may be rejected pending the severity of plagiarism. Therefore, if a manuscript uses a text copied directly from another source, this text must be written in quotation marks and the original source must be cited.

  • All articles must be written in English — preferably American English. SI units should be used. If you are not a native English speaker, you may want to utilize an external or Whioce Publishing’s optional professional language editing service before submitting the final version.

  • Whioce Publishing Pte Ltd offers its own professional editing services. By using this service, you can be sure that your English-language manuscript will be polished and ready for submission to your publication of choice at a very reasonable price. For further details about the Language Editing Services, please contact us at editorial@whioce.com. Please note that utilizing a language editing service is not a guarantee of acceptance.

  • Revised manuscripts must contain a detailed point by point response to the comments of the reviewers. The response to reviewers has to be uploaded as a separate file.

  • If you withdraw your manuscript after it has been accepted (but not yet published), you will be charged for costs incurred at USD200.

  • Authors are expected to have minimum amount of post-acquisition processing of data. In case of processing; alterations must be applied to the entire image (e.g., brightness, contrast, color balance). Any kind of alteration if being done has to be clearly stated in the figure legend and in Methods section.

    Grouping of data (e.g., cropping of images of removal of lanes from gels and bolts) must be made apparent and should be explicitly indicated in the appropriate figure legends. Data comparisons should only be made from comparative experiments, and individual data should not be utilized across multiple figures. If inappropriate image/data manipulation is identified after publication, we reserve the right to ask for the original data and, if that is not satisfactory, to issue a correction or retract the paper, as appropriate.

  • Whioce Publishing will preserve e-journals with Portico, ensuring that they will be secure and available into the future.

  • Cover Letter
    The cover letter is necessary for each submission. The cover letter should be uploaded as a separate file in Step 4 during the submission. The contents of the cover letter should include brief explanation of what was previously known, the conceptual advancement with the findings and its significance to broad readership. The cover letter will only be visible to the editor. Reviewers will not have access to the cover letter.

    Title
    The title should capture the conceptual significance for a broad audience. The title should not be more than 50 words and should be able to give readers an overall view of the paper’s significance. Titles should avoid using uncommon jargons, abbreviations and punctuations.

    Abstract
    The abstract should provide a brief summary of the paper. It should not contain any non-standard abbreviations, acknowledgements of support, references, footnotes or equations. The abstract should not exceed 200 words.

    Keywords
    Three to six keywords should be provided.

    Introduction
    The introduction section should provide a context or background that gives a broad readership an overall outlook of the field and the research performed. It tackles a problem and states its important regarding with the significance of the study. Introduction can conclude with a brief statement of the aim of the work and a comment about whether that aim was achieved.

    Materials and Methods
    The materials and methods section provides the general experimental design and methodologies used. The aim is to provide enough detail to for other investigators to fully replicate your results. It is also required to facilitate better understanding of the results obtained. Protocols and procedures for new methods must be included in detail to reproduce the experiments.

    Ethics
    Ethics information, including IACUC permit numbers and/or IRB name, if applicable. This information should be included in a subheading labeled "Ethics Statement" in the "Methods" section of your manuscript file, in as much detail as possible.

    Results
    The result section focuses on the results of the experiments performed. This section can be divided into subsections.

    Discussion and Conclusion
    The discussion and conclusion section should provide the significance of the results and identify the impact of the research in a broader context. It should not be redundant or similar to the content of the results section. Use the conclusion section for interpretation only, and not to summarize information already presented in the text or abstract.

    Author Contributions
    The author contributions section describes the contribution of each author, designated by initials. For the case of co-first authors, description of each author’s contribution is required.

    Acknowledgements
    The acknowledgements section should acknowledge contribution(s) from non-authors and funding sources. It should also include a declaration of any conflict of interest.

    Supplementary Information
    The supplementary information section is optional and contains all materials and figures that have been excluded from the entire manuscript. The information is relevant to the manuscript but remains non-essential to readers’ understanding of the manuscript’s main content. All supplementary information should be submitted as a separate file in Step 4 during manuscript submission. Please ensure the file names of such files start with ‘Suppl_info_’.

    Text
    The text of the manuscript should be in Microsoft Word. The length of the manuscript cannot be more than 8000 words.

    In-text citations
    Reference citations in the text should be numbered consecutively in square brackets. Some examples:

    1. Negotiation research spans many disciplines [3,4].
    2. This result was later contradicted by Becker and Seligman [5].
    3. This effect has been widely studied [1–3,7].

    Personal communications and unpublished works can only be used in the main text of the submission and are not to be placed in the Reference section. Authors are advised to limit such usage to the minimum. They should also be easily identifiable by stating the authors and year of such unpublished works or personal communications and the word ‘Unpublished’ in parenthesis. E.g. (Smith J, 2000, Unpublished)

    References
    The references section is compulsory and should be placed at the end of all manuscripts. The list of references should only include works that are cited in the text and that have been published or accepted for publication. Personal communications and unpublished works should be excluded from this section.

    The journal follows the Vancouver style of references. You can refer to the ICMJE Recommendation for preparing your references in the manuscript for submission. For references in the reference list, if the referred article has more than five authors, list only the first five authors and abbreviate the remaining authors to italicized ‘et al.’ (meaning: "and others"). Authors referenced are listed with their surname followed by their initials (e.g. Smith J). All references should be numbered (e.g. 1. 2. 3. etc.) and sequenced according to the order it appears as an in-text citation. References should follow the following pattern:

    • Journal article
      Terauchi Y, Takamoto I, Kubota N, Matsui J, Suzuki R, Komeda K, Hara A, Toyoda Y, Miwa I, Aizawa S, Tsutsumi S, Tsubamoto Y, Hashimoto S, Eto K, Nakamura A, Noda M, Tobe K, Aburatani H, Nagai R, Kadowaki T. Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. J Clin Invest 2007; 117(1): 246–57. doi: 10.1172/JCI17645.
    • Non-English journal article
      Massone L, Borghi S, Pestarino A, Piccini R, Gambini C. Localisations palmaires purpuriques de la dermatite herpetiforme (French) [Purpuric palmar sites of dermatitis herpetiformis]. Ann Dermatol Venerol 1987; 114(12): 1545–1547.
    • Book
      Rojko JL, Hardy WD Jr. Feline leukemia virus and other retroviruses. In: Sherding RG (editors). The cat: diseases and clinical management. New York: Churchill Livingstone; 1989. p. 229–332.
    • Proceedings
      Sasaki Y, Nomura Y (editors). Symposium on Nasal Polyp; 1984 Oct 5–6; Tokyo. Stockholm: Almqvist & Wiksell; 1986. p. 48.
    • Dissertations
      Jones DL. The role of physical activity on the need for revision total knee arthroplasty in individuals with osteoarthritis of the knee [PhD thesis]. Pittsburgh (PA): University of Pittsburgh; 2001. p. 436.
    • Patents
      Blanco EE, Meade JC, Richards WD (inventors). Ophthalmic V (assignee). Surgical Stapling system. US patent. 4,969,591. 1990 Nov 13.
    • Websites
      Hypertension, Dialysis & Clinical Nephrology [Internet]. Hinsdale (IL): Medtext, Inc.; 1995–2001 [cited 2001 Mar 8]. Available from: http://www.medtext.com/hdcn.htm.

    Tables, Lists and Equations
    Tables created using Microsoft Word table function are preferred. The tables should include a title. Titles and footnotes/legends should be concise. These must be submitted together with the manuscript. Likewise, lists and equations should be properly aligned and its meaning clear to readers.

    Figures
    Figures include photographs, scanned images, graphs, charts and schematic diagrams. Figures submitted should avoid unnecessary decorative effects (e.g. 3D graphs) as well as be minimally processed (e.g. changes in brightness and contrast applied uniformly for the entire figure). It should also be set against a white background. Please remember to label all figures (e.g. axis etc.) and add in captions (outside the figure) as required. All figures must have a brief title (also known as caption) that describes the entire figure without citing specific panels, followed by a legend defined as description of each panel.

    The preferred file formats are TIFF and JPEG. All figures should be legible in print form and of optimal resolution. Optimal resolutions preferred are 300 dots per inch for RBG colored, 600 dots per inch for greyscale and 1200 dots per inch for line art. Although there are no file size limitation imposed, authors are highly encouraged to compress their figures to an ideal size without unduly affecting legibility and resolution of figures. This will also speed up the process of uploading in the submission system.

    The Editor-in-Chief and Publisher reserve the right to request from author(s) the high-resolution files and unprocessed data and metadata files should the need arise at any point after manuscript submission for reasons such as production, evaluation or other purposes. The file name should allow for ease in identifying the associated manuscript submitted.

  • The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.

Article Processing Charges (APC)

Journal of Medicines Development Sciences is an Open Access Journal under Whioce Publishing. All articles published in Journal of Medicines Development Sciences are accessible electronically from the journal website without commencing any kind of payment. In order to ensure contents are freely available and maintain publishing quality, Article Process Charges (APC) is applicable to all authors who wish to submit their articles to the journal to cover the cost incurred in processing the manuscripts. Such cost will cover the peer-review, copyediting, typesetting, publishing, content depositing and archiving processes. Those charges are applicable only to authors who have their manuscript successfully accepted after peer-review.

Journal TitleAPC
Journal of Medicines Development Sciences$800

We encourage authors to publish their papers with us and don’t wish the cost of article processing fees to be a barrier especially to authors from the low and lower middle income countries/regions. A range of discounts or waivers are offered to authors who are unable to pay our publication processing fees. Authors can write in to apply for a waiver and requests will be considered on a case-by-case basis.

Authors based in these countries/regions listed below may apply to receive up to a 50%-100% waiver of the standard article processing fee; Waiver subjected to approval.

  • Afghanistan
  • Armenia
  • Bangladesh
  • Benin
  • Bhutan
  • Bolivia
  • Burkina Faso
  • Burundi
  • Cabo Verde
  • Cambodia
  • Cameroon
  • Central African Republic
  • Chad
  • Comoros
  • Congo, Dem. Rep
  • Congo, Rep.
  • Côte d'Ivoire
  • Djibouti
  • Egypt, Arab Rep.
  • El Salvador
  • Eritrea
  • Ethiopia
  • Gambia, The
  • Ghana
  • Guatemala
  • Guinea
  • Guinea-Bissau
  • Haiti
  • Honduras
  • India
  • Indonesia
  • Kenya
  • Kiribati
  • Korea, Dem. People's Rep.
  • Kosovo
  • Kyrgyz Republic
  • Lao PDR
  • Lesotho
  • Liberia
  • Madagascar
  • Malawi
  • Mali
  • Mauritania
  • Micronesia, Fed. Sts.
  • Moldova
  • Mongolia
  • Morocco
  • Mozambique
  • Myanmar
  • Nepal
  • Nicaragua
  • Niger
  • Nigeria
  • Pakistan
  • Papua New Guinea
  • Philippines
  • Rwanda
  • Samoa
  • São Tomé and Principe
  • Senegal
  • Sierra Leone
  • Solomon Islands
  • Somalia
  • South Sudan
  • Sri Lanka
  • Sudan
  • Swaziland
  • Syrian Arab Republic
  • Tajikistan
  • Tanzania
  • Timor-Leste
  • Togo
  • Tonga
  • Tunisia
  • Uganda
  • Ukraine
  • Uzbekistan
  • Vanuatu
  • Vietnam
  • West Bank and Gaza
  • Yemen, Rep.
  • Zambia
  • Zimbabwe

If you are residing in one of the above mentioned countries and need to apply for a waiver, please email our editorial department (editorial@whioce.com) with the following information:

  • Your name and institution with full address details
  • Title of journal you wish to submit a manuscript to
  • Reason for applying for a waiver
  • Title of your paper
  • Country of residence of all co-author

Frequently Asked Questions

  • Answer: To establish whether your paper is suitable for this journal, please read Focus and Scope under Editorial Policies.
  • Answer: Registration and login are required to submit manuscript online and to check the status of current submission.
  • Answer: The submission file can be submitted in OpenOffice, Microsoft Word, RTF, or WordPerfect document file format.
  • Answer: The length of the manuscript cannot be more than 8000 words.
  • Answer: The cover letter is necessary for each submission. The cover letter should be uploaded as a separate file in Step 4 during the submission. The contents of the cover letter should include brief explanation of what was previously known, the conceptual advancement with the findings and its significance to broad readership. The cover letter will only be visible to the editor. Reviewers will not have access to the cover letter.
  • Answer: You can suggest 2 reviewers for your submission. However, the decision of whether to invite them lies with the Editor.
  • Answer: This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. Refer to the Publication Fees tab for more details.

Announcements

 

Call for Papers

 

The Editor-in-Chief, Prof. Jean-Marie Boeynaems, invites all authors to submit manuscripts for peer-review.

The Journal of Medicines Development Sciences (JMDS) focuses on the discovery and development of new medicinal products. The journal publishes original research articles on medicinal chemistry, experimental pharmacology including pharmacokinetics, preclinical safety, clinical pharmacology, pharmacogenomics, clinical research, pharmacoepidemiology and pharmacoeconomics. The journal also publishes brief reports on new research findings and review articles. Articles encouraging taking the therapy from bench to bedside and creating a broad readership of young researchers, clinicians and scientists are welcome.

JMDS is currently indexed in JournalTOCs. Besides, articles published in JMDS can be searched in Scilit, CNKI Scholar and Google Scholar. JMDS is archived by Portico and the National Library Board of Singapore.

Why Publish With Us?

  • Universal access and visibility of research results
  • Submitted articles are peer-reviewed by a global list of reviewers
  • Authors maintain the copyright to the published articles
  • Authors from low and lower middle income countries who are unable to pay the publication charges can write in to apply for a waiver through editorial@whioce.com
 
Posted: 2017-08-18
 
More Announcements...